Literature DB >> 17167516

Cancer phenomics: RET and PTEN as illustrative models.

Kevin M Zbuk1, Charis Eng.   

Abstract

Cancer phenomics, the systematic acquisition and objective documentation of host and/or somatic cancer phenotypic data at many levels, is a young field compared with other molecular-based 'omics'. Two relatively advanced phenomic paradigms are associated with phosphatase and tensin homologue (PTEN) and rearranged during transfection (RET), genes that are associated with cancer predisposition syndromes in addition to developmental disorders. The phenomic characterization of PTEN and RET underscores the importance of incorporating robust phenomics into the host 'omic' profile, and shows that the evolution of phenomics will be crucial to the advancement of personalized medicine.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17167516     DOI： 10.1038/nrc2037

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  88 in total

Review 1.  Involvement of members of the cadherin superfamily in cancer.

Authors:  Geert Berx; Frans van Roy
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09-23       Impact factor: 10.005

2.  Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion.

Authors:  Utpal K Mukhopadhyay; Patrick Mooney; Lilly Jia; Robert Eves; Leda Raptis; Alan S Mak
Journal:  Mol Cell Biol       Date:  2010-08-23       Impact factor: 4.272

Review 3.  Selection of extreme phenotypes: the role of clinical observation in translational research.

Authors:  José Luis Pérez-Gracia; Alfonso Gúrpide; María Gloria Ruiz-Ilundain; Carlos Alfaro Alegría; Ramon Colomer; Jesús García-Foncillas; Ignacio Melero Bermejo
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

4.  Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.

Authors:  Joanne Ngeow; Jessica Mester; Lisa A Rybicki; Ying Ni; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

5.  A novel PTEN gene promoter mutation and untypical Cowden syndrome.

Authors:  Chen Liu; Guangbing Li; Rongrong Chen; Xiaobo Yang; Xue Zhao; Haitao Zhao
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

6.  A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling.

Authors:  Fang Feng; Lamis Yehia; Ying Ni; Yi Seok Chang; Sissy Meihua Jhiang; Charis Eng
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

Review 7.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

Review 8.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

9.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

10.  A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.

Authors:  Panomwat Amornphimoltham; Vyomesh Patel; Kantima Leelahavanichkul; Robert T Abraham; J Silvio Gutkind
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.